Skip to content
Imjudo, Tremelimumab astrazeneca(tremelimumab)
Imjudo (tremelimumab) is an antibody pharmaceutical. Tremelimumab was first approved as Imjudo on 2022-10-21. It is used to treat hepatocellular carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma and non-small-cell lung carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Imjudo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tremelimumab
Tradename
Proper name
Company
Number
Date
Products
Imjudotremelimumab-actlAstraZenecaN-761289 RX2022-10-21
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
imjudoBiologic Licensing Application2022-10-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatocellular carcinoma—D006528C22.0
Agency Specific
FDA
EMA
Expiration
Code
tremelimumab, Imjudo, AstraZeneca AB
2029-10-21Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
918 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD00854510713717214237
Renal cell carcinomaD002292212871—53
Lung neoplasmsD008175C34.90111441126
Kidney neoplasmsD007680EFO_0003865C6446—1111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8065653—1101
Non-small-cell lung carcinomaD002289375516——91
Prostatic neoplasmsD011471C6117292——43
Colorectal neoplasmsD01517920262——40
Squamous cell carcinoma of head and neckD00007719518201——32
Liver neoplasmsD008113EFO_1001513C22.012215——32
Small cell lung carcinomaD05575210103——20
Urinary bladder neoplasmsD001749C676141——17
SarcomaD0125098121——17
GlioblastomaD005909EFO_0000515772—116
Show 13 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C252118———34
Breast neoplasmsD001943EFO_0003869C501717——232
Uveal neoplasmsD014604EFO_10012301315———24
Ovarian neoplasmsD010051EFO_0003893C561213———19
Urologic neoplasmsD014571C64-C68118———14
AdenocarcinomaD000230211———13
Uterine cervical neoplasmsD00258386——113
Myelodysplastic syndromesD009190D46102———12
Non-hodgkin lymphomaD008228C85.997———12
Myeloid leukemia acuteD015470C92.0101———11
Show 136 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003404————4
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.23————3
Primary myelofibrosisD055728D47.42————2
Ovarian epithelial carcinomaD0000772162————2
AnemiaD000740EFO_0004272D64.91————1
Myeloid leukemia chronic-phaseD0154661————1
ThrombocytosisD013922D75.831————1
Small cell carcinomaD0182881————1
Female genital neoplasmsD0058331————1
HydronephrosisD006869EFO_0005562N13.301————1
Show 16 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTREMELIMUMAB
INNtremelimumab
Description
Tremelimumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)TREMELIMUMAB
Structure (InChI/SMILES or Protein Sequence)
>5GGV:H|heavy chain QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLY LQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH >5GGV:L|light chain DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5GGU, 5GGV
CAS-ID745013-59-6
RxCUI—
ChEMBL IDCHEMBL2108658
ChEBI ID—
PubChem CID—
DrugBankDB11771
UNII IDQEN1X95CIX (ChemIDplus, GSRS)
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
1493
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
P16410
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,508 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,425 adverse events reported
View more details